Shares of RadNet, Inc. (NASDAQ:RDNT – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $90.00.
Several research analysts have recently issued reports on the company. Jefferies Financial Group reaffirmed a “buy” rating on shares of RadNet in a research note on Friday, July 31st. Zacks Research upgraded shares of RadNet from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of RadNet in a report on Friday, August 7th. Raymond James Financial restated a “strong-buy” rating on shares of RadNet in a research report on Tuesday, September 22nd. Finally, Barclays raised their price target on shares of RadNet from $65.00 to $79.00 and gave the company an “overweight” rating in a research note on Friday, August 28th.
Check Out Our Latest Stock Analysis on RDNT
Institutional Trading of RadNet
RadNet Trading Up 0.9%
NASDAQ RDNT opened at $70.57 on Friday. The company has a market cap of $5.55 billion, a price-to-earnings ratio of -261.36 and a beta of 1.41. RadNet has a twelve month low of $50.82 and a twelve month high of $85.84. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.94. The business’s fifty day moving average is $72.87 and its 200 day moving average is $63.29.
RadNet (NASDAQ:RDNT – Get Free Report) last issued its earnings results on Monday, August 10th. The medical research company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.09. RadNet had a positive return on equity of 2.61% and a negative net margin of 0.93%.The business had revenue of $622.72 million during the quarter, compared to analysts’ expectations of $610.87 million. During the same quarter in the prior year, the firm earned $0.31 EPS. The business’s revenue for the quarter was up 25.0% compared to the same quarter last year. As a group, sell-side analysts expect that RadNet will post 0.49 EPS for the current fiscal year.
RadNet Company Profile
RadNet, Inc is an outpatient diagnostic imaging company that provides medical imaging services through a network of ambulatory imaging centers. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET/CT), mammography, ultrasound, X-ray, fluoroscopy and other diagnostic examinations.
The company serves patients, physicians, hospitals and health systems, with operations concentrated in several U.S. markets, including California, Delaware, Maryland, New Jersey and New York.
See Also
- Five stocks we like better than RadNet
- NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run
- A Manufacturing Surprise Could Be a Big Win for These 2 Companies
- What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions
- 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.
